LOGIN  |  REGISTER
Viking Therapeutics
Viking Therapeutics

Modivcare to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference

September 21, 2023 | Last Trade: US$11.13 0.24 2.20

DENVER / Sep 21, 2023 / Business Wire / Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced that Heath Sampson, Modivcare’s President and Chief Executive Officer, is scheduled to participate in a fireside chat presentation at the Deutsche Bank 31st Annual Leveraged Finance Conference on Tuesday, October 3, 2023 at 8:00 a.m. (PDT). Management, including Barbara Gutierrez, Modivcare’s Chief Financial Officer, will host investor meetings throughout the day.

A link to the live webcast of the Company’s presentation can be found here or on Modivcare’s Investor Relations website at Modivcare Inc. - Investor Overview. A replay of the presentation will be available for 90 days following the date of the presentation.

About Modivcare

Modivcare Inc. (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their members. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal care and remote patient monitoring. To learn more about Modivcare, please visit www.modivcare.com.

C4 Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB